This is a working overview of Chelation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Gly-His-Lys | Tripeptide; copper binds via His and N-terminus |
| Copper stoichiometry | Typically 1 Cu(II) per peptide | Can form ternary complexes under some conditions |
| Molecular formula (peptide) | C14H24N6O4 | Free peptide; copper complex mass differs |
| Appearance (solid) | Blue to blue-green powder | Color derives from copper d-d transitions |
| Solubility | Soluble in water and polar solvents | Solubility depends on pH and counterions |
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Etizolam is a drug of potential misuse. Cases of etizolam dependence have been documented in the medical literature. Since 1991, cases of etizolam misuse and addiction have substantially increased, due to varying levels of accessibility and cultural popularity. Pills being sold as Xanax or other benzodiazepines that are illicitly manufactured may often contain etizolam rather than their listed ingredient
In biology, a sequence motif is a nucleotide or amino-acid sequence pattern that is widespread and usually assumed to be related to biological function of the macromolecule. For example, an N-glycosylation site motif can be defined as Asn, followed by anything but Pro, followed by either Ser or Thr, followed by anything but Pro residue.
Psilocybin oral: 5–6 hours LSD oral: 7–11 hours (dose-dependent) Mescaline oral: 10–11 hours (range 6–14 hours) (dose-dependent) Dimethyltryptamine (DMT) inhaled: 5–20 minutes Ayahuasca (oral DMT with an MAOITooltip monoamine oxidase inhibitor): 4–6 hours 5-MeO-DMT inhaled: 5–20 minutes 2C-B oral: 3–5 hours (range 2–8 hours) The shortest-acting oral psychedelics are the less-well-known ASR-3001 (5-MeO-iPALT) (1.5–2.5 hours) and 4-HO-DiPT (2–3 hours), while the longest-acting known psychedelic is 2C-G-5 (32–48 hours). However, DOx psychedelics like DOM and the FLY psychedelic Bromo-DragonFLY (DOB-DFLY) reportedly may produce effects lasting for up to a few days at high doses.
Sources: en.wikipedia.org
Monazite can form in fabrics caused by deformation. Monazite may be present as elongate grains aligned in foliation. It can be interpreted that either the monazite formed before the shearing and was aligned during shearing, or formed at the same time as the shearing. It thus provides an upper limit of the shearing age. For example, if the monazite is dated 800 Ma, the age of shearing cannot be older than 800 Ma. However, it can also be interpreted that the monazite grew along the foliation of other minerals long after the shearing. This problem can be solved by analysing the compositional domains of monazite. Monazite along existing foliation would have a tendency to grow at the two ends along the foliation. If we can find monazite overgrowths with different compositions and ages along at the two opposite ends of the grain, it is likely that the date of the monazite overgrowth is younger than the shearing.
== Contraindications == Sodium hyaluronate has a very low incidence of side effects, however it is contraindicated in people who are sensitive to hyaluronate preparations. If being administered as an intra-articular injection, it should not be given when there are infections or skin disease at the injection site.
Trends in obesity prevalence show no increase among youth since 2003–2004, but trends do show increases in both adults and youth from 1999 to 2000 through 2013–2014. No significant differences between 2011 and 2012 and 2013–2014 were seen in either youth or adults. Under pressure from parents and anti-obesity advocates, many school districts moved to ban sodas, junk foods, and candy from vending machines and cafeterias. State legislators in California, for example, passed laws banning the sale of machine-dispensed snacks and drinks in elementary schools in 2003, despite objections by the California-Nevada Soft Drink Association. The state followed more recently with legislation to prohibit their soda sales in high schools starting July 1, 2009, with the shortfall in school revenue to be compensated by an increase in funding for school lunch programs. A similar law passed by the Connecticut General Assembly in June 2005 was vetoed by governor Jodi Rell, who stated the legislation "undermines the control and responsibility of parents with school-aged children." In mid-2006, the American Beverage Association (including Cadbury, Coca-Cola, and PepsiCo) agreed to a voluntary ban on the sale of all high-calorie drinks and all beverages in containers larger than 8, 10 and 12 ounces in elementary, middle and high schools, respectively. There have been many strategies to try to control obesity issues. One cost-effective population-level change is taxes on sugary drinks. Interventions such as taxes can be a powerful way to improve the economic landscape of the food environment.
== Tributes == "Referring to the death of Professor Brailsford Robertson yesterday, the Prime Minister (Mr. Scullin) said:— His untimely end has robbed Australia of a brilliant scientist, whose contribution to the Commonwealth's progress would always be remembered. On behalf of the Federal Ministry Mr. Scullin extended his sincere sympathy to Professor Robertson's family, and expressed its appreciation of the great national services which he had rendered." The Argus, 20 January 1930. "Professor Brailsford Robertson was one of Australia's most brilliant scientists. The value of the work he was accomplishing cannot be estimated." Hon. R.L. Butler, Premier of South Australia, 20 January 1930. "The main purpose of [Robertson's] studies was to solve the mystery of physical life in it successive stages of commencement, growth, decline, and cessation, for the benefit of his fellow-men. ... The amount of original work he accomplished in his short life was prodigious. I would be rash to assert that the loss to science, or as I should prefer to say, the loss to humanity, caused by his death is irreparable, but it will probably be a long time before anyone else is able to gather the threads together and produce the fabric he was attempting to weave on his loom." Sir George Murray, Chancellor of the University of Adelaide, 18 March 1932.
Sources: en.wikipedia.org
Surgery may be done either by opening the chest or from inside the blood vessel. Dissections that involve only the second part of the aorta can typically be treated with medications that lower blood pressure and heart rate, unless there are complications which then require surgical correction. Complications that require surgical correction include blood leaking outside of the aorta, or reduced blood flow to organs due to the dissection causing a blockage of blood vessels that branch from the aorta. AD is relatively rare, occurring at an estimated rate of three per 100,000 people per year. It is more common in men than women. The typical age at diagnosis is 63, with about 10% of cases occurring before the age of 40. Without treatment, about half of people with Stanford type A dissections die within three days and about 10% of people with Stanford type B dissections die within one month. The first case of AD was described in the examination of King George II of Great Britain following his death in 1760. Surgery for AD was introduced in the 1950s by Michael E. DeBakey.
Myocardial infarction (MI) refers to tissue death (infarction) of a part of the heart muscle (myocardium), caused by ischemia, the lack of oxygen delivery to myocardial tissue. It is a type of acute coronary syndrome, which describes a sudden or short-term change in symptoms related to blood flow to the heart. Unlike the other type of acute coronary syndrome, unstable angina, a myocardial infarction occurs when there is cell death, which can be estimated by a blood test that measures biomarkers (the cardiac protein troponin). When there is evidence of an MI, it may be classified as an ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) based on the results of an ECG. Another approach suggests categorizing MI as either occlusion myocardial infarction (OMI) or non-occlusion myocardial infarction (NOMI), depending on evidence of coronary occlusion on ECG. Preliminary research suggests that using OMI/NOMI above STEMI/NSTEMI leads to improved clinical outcomes, as such terminology does not limit the diagnosis of acute coronary occlusion to current STEMI criteria, which alone have poor sensitivity for MI. The phrase "heart attack" is often used non-specifically to refer to myocardial infarction. An MI is different from—but can cause—cardiac arrest, where the heart is not contracting at all or so poorly that all vital organs cease to function, thus leading to death. It is also distinct from heart failure, in which the pumping action of the heart is impaired. However, an MI may lead to heart failure.
== Cost == In Canada, PET scan funding varies by province. In Ontario, as of October 2025, there is no charge to the patient for any PET scans funded as part of the PET Scans Ontario Program. The program funds routine PET services for indications where sufficient evidence exists that the scan benefits the patient and offers advantages over other imaging tests. In the United States, PET scan costs vary significantly by location, facility type, and insurance status. According to Medicare's 2026 payment data, a whole-body PET scan has a national average total cost of $872, with the patient paying approximately $174 after Medicare coverage. In the United Kingdom, the National Health Service provides PET-CT scans free at point of use for eligible patients. In Australia, Medicare subsidies are available for eligible PET services.
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low and vary with physiological state. Its natural functions are not fully established.
Copper binding changes the peptide's charge, shape, and reactivity. The complex can participate in redox chemistry and interact with proteins differently than the free peptide. These differences are why studies specify whether they used GHK or GHK-Cu.
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.